In vitro additive interaction between ketoconazole and antimony against intramacrophage Leishmania (Leishmania) amazonensis amastigotes
Open Access
- 29 June 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (6) , e0180530
Abstract
Leishmaniasis is a group of diseases caused by protozoa of Leishmania genus. The currently available treatments for this disease are expensive, present high toxicity and are associated to difficulties of healing and parasite resistance. Therefore, the development of strategies for leishmaniasis treatment is indispensable and includes reposition of existing drugs, as well as drug combination therapy. The aim of this study was to assess the nature of ketoconazole and antimony association on the cytotoxic effect against Leishmania (Leishmania) amazonensis amastigotes. The calculated mean sum of fractional 50% inhibitory concentration ( ΣFIC50) was 2.54 and 1.43 for free and intracellular amastigotes, respectively, values that suggest an additive interaction between ketoconazole and antimony concerning to Leishmania toxicity only in the intramacrophage parasite form. Despite the clinical efficacy of ketoconazole-antimony combination has been shown in the literature, our study is the first to describe the nature of ketoconazole-antimony interaction against L. (L.) amazonensis amastigotes. Moreover, our results point out the need for future in vivo studies to confirm the nature of ketoconazole-antimony interaction and also to determine possible effective dosage regimens related to ketoconazole administration in association with the optimal lower dose of antimony.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (479000/2013-1)
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais (APQ-02731-08)
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais (APQ-00376-10)
This publication has 35 references indexed in Scilit:
- Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator—PicrolivActa Tropica, 2011
- Use of Antimony in the Treatment of Leishmaniasis: Current Status and Future DirectionsMolecular Biology International, 2011
- In vitro interactions between sitamaquine and amphotericin B, sodium stibogluconate, miltefosine, paromomycin and pentamidine against Leishmania donovaniJournal of Antimicrobial Chemotherapy, 2011
- Intralesional sodium stibogluconate alone or its combination with either intramuscular sodium stibogluconate or oral ketoconazole in the treatment of localized cutaneous leishmaniasis: a comparative studyJournal of the European Academy of Dermatology and Venereology, 2010
- Defining Fractional Inhibitory Concentration Index Cutoffs for Additive Interactions Based on Self-Drug Additive Combinations, Monte Carlo Simulation Analysis, andIn Vitro-In VivoCorrelation Data for Antifungal Drug Combinations againstAspergillus fumigatusAntimicrobial Agents and Chemotherapy, 2010
- Sterol Biosynthesis Pathway as Target for Anti-trypanosomatid DrugsInterdisciplinary Perspectives on Infectious Diseases, 2009
- Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination StudiesPharmacological Reviews, 2006
- Identification and antimicrobial susceptibility of micro-organisms recovered from cutaneous lesions of human American tegumentary leishmaniasis in Minas Gerais, BrazilJournal of Medical Microbiology, 2005
- Protozoan genomics for drug discoveryNature Biotechnology, 2005
- Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasisJournal of Dermatological Treatment, 2001